EUCTR2012-000601-74-IE进行中（未招募）1 期
A Randomized, Controlled, Open-Label, Multicenter Phase 3 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, Versus Temsirolimus in Subjects with Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy - NAP
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 280
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Confirmed diagnosis of mantle cell lymphoma (MCL)
- •- Received at least 1 prior rituximab-containing chemotherapy regimen (separate lines of therapy are defined as single or combination therapies that are either separated by disease progression or by a > 6 month treatment-free interval)
- •- Documented relapse or disease progression following the last anti-MCL treatment
- •- At least 1 measurable site of disease according to Revised Response Criteria for Malignant Lymphoma
- •- Eastern Cooperative Oncology Group performance status grade 0 or 1
- •- Protocol-defined hematology and biochemical laboratory values
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 84
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 196
排除标准
- •- Prior nitrosoureas within 6 weeks, chemotherapy within 3 weeks, therapeutic anticancer antibodies within 4 weeks, radio- or toxin-immunoconjugates within 10 weeks, radiation therapy or other investigational agents within 3 weeks, or major surgery within 4 weeks of randomization
- •- Prior treatment with temsirolimus, other mTOR inhibitors, ibrutinib, or other Bruton’s tyrosine kinase (BTK) inhibitors
- •- Known central nervous system lymphoma
- •- Received an allogeneic or autologous hematopoietic stem cell transplant <=6 months from the date of randomization and on immunosuppressive therapy or have evidence of active graft versus host disease
- •- Diagnosed or treated for malignancy other than MCL, except: malignancy treated with curative intent and with no known active disease present for >=3 years before randomization, adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease, adequately treated cervical carcinoma in situ without evidence of disease
- •- History of stroke or intracranial hemorrhage within 6 months prior to randomization
- •- Requires anticoagulation with warfarin or equivalent vitamin K antagonist
- •- Requires treatment with strong CYP3A inhibitors
- •- Clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of Screening, or any Class 3 (moderate) or Class 4 (severe) cardiac disease as defined by the New York Heart Association Functional Classification
- •- Known history of human immunodeficiency virus (HIV) or active hepatitis C virus (HCV) or active hepatitis B virus (HBV) infection or any uncontrolled active systemic infection requiring intravenous antibiotics
- •- Woman who is pregnant or breast-feeding
- •- Any life-threatening illness, medical condition, or organ system dysfunction which, in the investigator’s opinion, could compromise the subject’s safety, interfere with the absorption or metabolism of ibrutinib capsules, or put the study outcomes at undue risk
研究者
相似试验
进行中（未招募）
1 期
A Study of Ibrutinib (a Bruton’s Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior TherapyRelapsed or refractory Mantle Cell LymphomaMedDRA version: 17.0Level: PTClassification code 10026801Term: Mantle cell lymphoma refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-000601-74-CZJanssen-Cilag International NV280
进行中（未招募）
1 期
A Study of Ibrutinib (a Bruton’s Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior TherapyRelapsed or refractory Mantle Cell LymphomaMedDRA version: 17.0Level: PTClassification code 10026801Term: Mantle cell lymphoma refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-000601-74-HUJanssen-Cilag International NV280
进行中（未招募）
1 期
A Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior TherapyRelapsed or refractory Mantle Cell LymphomaMedDRA version: 14.1Level: LLTClassification code 10026808Term: Mantle zone lymphoma refractorySystem Organ Class: 100000004864MedDRA version: 14.1Level: LLTClassification code 10026807Term: Mantle zone lymphoma recurrentSystem Organ Class: 100000004864MedDRA version: 14.1Level: LLTClassification code 10026806Term: Mantle zone lymphomaSystem Organ Class: 100000004864EUCTR2012-000601-74-ITJANSSEN-CILAG INTERNATIONAL N.V.280
进行中（未招募）
1 期
A Study of Ibrutinib (a Bruton’s Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior TherapyEUCTR2012-000601-74-NLJanssen-Cilag International NV280
进行中（未招募）
1 期
A Study of Ibrutinib (a Bruton’s Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior TherapyRelapsed or refractory Mantle Cell LymphomaMedDRA version: 19.0 Level: PT Classification code 10026801 Term: Mantle cell lymphoma refractory System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-000601-74-GBJanssen-Cilag International NV280